We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

In need of a breather

23 July 2014 By Neil Unmack

The UK drugmaker no longer thinks it can grow earnings in 2014. Sales are being hit by price pressure and generic competition. Debt limits GSK’s ability to buy its way out of trouble; Chinese probes look like a poison pill to a tax-inverting merger. The stock is cheap for a reason.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)